Vertex adds a new gene editing partner, paying Obsidian $75M for controllable CRISPR system

Jason Mast

Editor

When Paul Wotton became CEO of Obsidian Therapeutics two years ago, he asked his team to explore where they could apply the company’s technology beyond …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Vertex adds a new gene editing partner, paying Obsidian $75M for controllable CRISPR system

Jason Mast

Editor

Sign up to read this article for free.

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Are programs with compounded GLP-1s safe for your population?

Ver­tex adds a new gene edit­ing part­ner, pay­ing Ob­sid­i­an $75M for con­trol­lable CRISPR sys­tem

Jason Mast

Editor

Sign up to read this article for free.

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

Vertex adds a new gene editing partner, paying Obsidian $75M for controllable CRISPR system

NewAmsterdam aces Phase 3 trial, but investors are skeptical

Pfizer partners with two more Flagship biotechs on obesity, cancer

Post-Hoc: RFK vs. Vivek, and the future of US drug policy

FDA updates label of 33-year-old cancer drug with new dose and warning

Carolyn Bertozzi’s latest biotech debuts with $30M seed round and a sugary spin on immunotherapy

Are programs with compounded GLP-1s safe for your population?